PD-1/PD-L1

PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitor anticancer drugs that block the activity of PD-1 and PDL1 immune checkpoint proteins present on the surface of cells. Immune checkpoint inhibitors are emerging as a front-line treatment for several types of cancer.

Cat. No.	Product name	CAS No.	Purity	Chemical Structure
T4696	BMS202 hydrochloride (1675203-84-5(free base))	2089334-95-0	98%
T4696	BMS202 hydrochloride (1675203-84-5(free base)) (PD-1/PD-L1 inhibitor 2 hydrochloride) is a small-molecule PD-1/PD-L1 interaction inhibitor (IC50: 18 nM). Biophys...
T78053	PD-L1-IN-2	2894733-91-4	98%
T78053	PD-L1-IN-2, a Naamidine J derivative, serves as a promising antineoplastic immunomodulator by hindering PD-L1 activity. In vivo studies indicate that it suppress...
T78222	(D)-PPA 1 TFA		98%
T78222	(D)-PPA 1 TFA is a hydrolysis-resistant D-peptide antagonist and a potent PD-1/PD-L1 inhibitor, exhibiting an affinity for PD-1 of 0.51 μM and demonstrating effi...
T78269	Anti-Mouse PD-1 Antibody (RMP1-14)		98%	Anti-Mouse PD-1 Antibody (RMP1-14)
T78269	RMP1-14 is an IgG1-like immunoglobulin and anti-Mouse PD-1 antibody that blocks PD-1/PD-L1 signaling.			Anti-Mouse PD-1 Antibody (RMP1-14)
T78270	Anti-Mouse PD-L1 Antibody (10F.9G2)		98%	Anti-Mouse PD-L1 Antibody (10F.9G2)
T78270	Anti-Mouse PD-L1 Antibody is a rat-derived IgG2b monoclonal antibody that inhibits mouse PD-L1.			Anti-Mouse PD-L1 Antibody (10F.9G2)
T78330	Peresolimab	2411580-63-5	98%	Peresolimab
T78330	Peresolimab, a humanized IgG1-κ antibody, targets PD-1 and may activate physiological immune inhibitory pathways, thereby restoring immune homeostasis [1] [2].			Peresolimab
T78755	PD-1/PD-L1-IN-31		98%
T78755	PD-1/PD-L1-IN-31 is a potent inhibitor of PD-1/PD-L1 (IC50=2.2 nM) that enhances IFN-γ secretion and activates the immune response of peripheral blood mononuclea...
T79205	PD-1/PD-L1-IN-34	2924403-17-6	98%
T79205	PD-1/PD-L1-IN-34 (Compound (1S,2S)-A25) effectively inhibits the PD-1/PD-L1 interaction (IC 50 = 0.029 μM) and demonstrates selective binding affinity to PD-L1 (...
T79314	PD-L1-IN-3		98%
T79314	PD-L1-IN-3 (Compound 4a) functions as an inhibitor targeting the PD-1/PD-L1 axis, with an IC50 value of 4.97nM for PD-L1 inhibition and an EC50 value of 2.70 μM ...
T79528	SWS1	2922115-32-8	98%
T79528	SWS1, a d-(+)-biotin-conjugated PD-L1 inhibitor (IC50: 1.8 nM), displays anticancer activity by augmenting tumor-infiltrating lymphocytes and demonstrating anti-...
T79576	PD-1/PD-L1-IN-32		98%
T79576	PD-1/PD-L1-IN-32 (compound A56) is a potent inhibitor of PD-1/PD-L1, displaying pronounced anticancer activity with an IC50 value of 2.4 nM. It effectively suppr...
T79643	PD-1/PD-L1-IN-33	2975602-78-7	98%
T79643	PD-1/PD-L1-IN-33 (Compound N11), a PD-1/PD-L1 inhibitor, effectively impedes the interaction between PD-1 and PD-L1 with an IC50 of 6.3 nM. By doing so, it enhan...
T79705	LP23		98%
T79705	LP23, a non-arylmethylamine PD-1/PD-L1 inhibitor (IC 50: 16.7 nM), exhibits anti-tumor activity through the restoration of immune cell function in HepG2/Jurkat T...
T80209	Human membrane-bound PD-L1 polypeptide	1831010-13-9	98%	Human membrane-bound PD-L1 polypeptide
T80209	Human membrane-bound PD-L1 polypeptide serves as an antigen for inducing the production of PD-L1 antibodies [1].			Human membrane-bound PD-L1 polypeptide
T80569	Benmelstobart	2303884-58-2	98%	Benmelstobart
T80569	Benmelstobart, an IgG1κ antibody, targets PD-L1/CD274 and is of murine origin [1].			Benmelstobart
T80582	Acrixolimab	2506324-29-2	98%	Acrixolimab
T80582	Acrixolimab is a humanized IgG4-κ monoclonal antibody that selectively targets PD-1 [1] [2].			Acrixolimab
T80611	Sasanlimab	2206792-50-7	98%	Sasanlimab
T80611	Sasanlimab (PF-06801591), a humanized IgG4-κ antibody, selectively targets PD-1 and is primarily produced in Chinese Hamster Ovary (CHO) cells [1].			Sasanlimab
T80617	Reozalimab	2445259-99-2	98%	Reozalimab
T80617	Rezilimab is a bispecific antibody that targets PD-1/PD-L1 and mediates antibody-dependent cell cytotoxicity (ADCC) in cancer research [1] [2].			Reozalimab
T80619	Rosnilimab	2412764-40-8	98%	Rosnilimab
T80619	Rosnilimab is a humanized IgG1-κ antibody that targets PD-1 [1] [2].			Rosnilimab
T80863	Visugromab	2556646-63-8	98%	Visugromab
T80863	Visugromab, a GDF-15 neutralizing IgG4 monoclonal antibody (mAb), demonstrates potent efficacy in treating PD-1/PD-L1 relapsed/refractory metastatic solid tumors...			Visugromab